Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)
Status:
Terminated
Trial end date:
2009-06-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of FG-3019 administered
over 8 weeks to adolescent and adult subjects with steroid-resistant focal segmental
glomerulosclerosis (FSGS).